Andrew D Huber
Overview
Explore the profile of Andrew D Huber including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
431
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Puray-Chavez M, Farghali M, Yapo V, Huber A, Liu D, Ndongwe T, et al.
Viruses
. 2019 Jul;
11(7).
PMID: 31319455
Moloney leukemia virus 10 (MOV10) is an RNA helicase that has been shown to affect the replication of several viruses. The effect of MOV10 on Hepatitis B virus (HBV) infection...
22.
Huber A, Chen T
Cell Chem Biol
. 2019 Mar;
26(3):314-316.
PMID: 30901558
In this issue of Cell Chemical Biology, Mo et al. (2019) report the development and validation of a co-culture system with cancer and immune cells that is suitable for high-throughput...
23.
Tang J, Do H, Huber A, Casey M, Kirby K, Wilson D, et al.
Eur J Med Chem
. 2019 Feb;
166:390-399.
PMID: 30739822
The pharmacophore of active site inhibitors of human immunodeficiency virus (HIV) reverse transcriptase (RT)-associated RNase H typically entails a flexible linker connecting the chelating core and the hydrophobic aromatics. We...
24.
Tang J, Huber A, Pineda D, Boschert K, Wolf J, Kankanala J, et al.
Eur J Med Chem
. 2018 Dec;
164:179-192.
PMID: 30594676
Chronic hepatitis B virus (HBV) infection represents a major health threat. Current FDA-approved drugs do not cure HBV. Targeting HBV core protein (Cp) provides an attractive approach toward HBV inhibition...
25.
Huber A, Pineda D, Liu D, Boschert K, Gres A, Wolf J, et al.
ACS Infect Dis
. 2018 Dec;
5(5):750-758.
PMID: 30582687
An estimated 240 million are chronically infected with hepatitis B virus (HBV), which can lead to liver disease, cirrhosis, and hepatocellular carcinoma. Currently, HBV treatment options include only nucleoside reverse...
26.
Wang L, Tang J, Huber A, Casey M, Kirby K, Wilson D, et al.
Eur J Med Chem
. 2018 Jul;
156:680-691.
PMID: 30031978
Human immunodeficiency virus (HIV) reverse transcriptase (RT)-associated ribonuclease H (RNase H) remains an unvalidated drug target. Reported HIV RNase H inhibitors generally lack significant antiviral activity. We report herein the...
27.
Wang L, Tang J, Huber A, Casey M, Kirby K, Wilson D, et al.
Eur J Med Chem
. 2018 Jul;
156:652-665.
PMID: 30031976
Human immunodeficiency virus (HIV) reverse transcriptase (RT) associated ribonuclease H (RNase H) remains the only virally encoded enzymatic function not targeted by current drugs. Although a few chemotypes have been...
28.
Huber A, Wolf J, Liu D, Gres A, Tang J, Boschert K, et al.
mSphere
. 2018 Apr;
3(2).
PMID: 29669885
Heteroaryldihydropyrimidines (HAPs) are compounds that inhibit hepatitis B virus (HBV) replication by modulating viral capsid assembly. While their biophysical effects on capsid assembly have been previously studied, the effect of...
29.
Puray-Chavez M, Tedbury P, Huber A, Ukah O, Yapo V, Liu D, et al.
Nat Commun
. 2017 Dec;
8(1):1882.
PMID: 29192235
Technical limitations in simultaneous microscopic visualization of RNA, DNA, and proteins of HIV have curtailed progress in this field. To address this need we develop a microscopy approach, multiplex immunofluorescent...
30.
Kankanala J, Kirby K, Huber A, Casey M, Wilson D, Sarafianos S, et al.
Eur J Med Chem
. 2017 Oct;
141:149-161.
PMID: 29031062
Human immunodeficiency virus (HIV) reverse transcriptase (RT) associated ribonuclease H (RNase H) is the only HIV enzymatic function not targeted by current antiviral drugs. Although various chemotypes have been reported...